Olaparib-induced cutaneous vasculitis in a patient with recurrent ovarian cancer

Eur J Dermatol. 2022 Sep 1;32(5):655-656. doi: 10.1684/ejd.2022.4343.
No abstract available

MeSH terms

  • Chronic Disease
  • Female
  • Humans
  • Ovarian Neoplasms* / drug therapy
  • Phthalazines / adverse effects
  • Piperazines / adverse effects
  • Recurrence
  • Vasculitis*

Substances

  • olaparib
  • Phthalazines
  • Piperazines